Ashwagandha for Women: Hormones, Fertility, and Menopause

What ashwagandha is and how it acts on the stress-hormone axis

Ashwagandha (Withania somnifera) is a botanical adaptogen used in Ayurvedic medicine for over 3,000 years. The active constituents are withanolides, a group of steroidal lactones that modulate the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress response system. When the HPA axis is chronically activated by stress, cortisol remains elevated, which disrupts the hypothalamic-pituitary-gonadal (HPG) axis, the hormonal cascade that regulates estrogen, progesterone, and ovulation. This matters for women because chronically elevated cortisol suppresses gonadotropin-releasing hormone (GnRH) secretion, which in turn reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both essential for ovulation and menstrual regularity.

Beyond cortisol modulation, ashwagandha provides additional hormonal support through several mechanisms:

• Reduces markers of oxidative stress, which can damage ovarian follicles and impair egg quality.
• Modulates GABA receptors, contributing to anxiolytic effects that reduce the physiological burden of chronic stress.
• Decreases inflammatory cytokines that interfere with normal reproductive hormone signaling.

The evidence for ashwagandha in female hormonal health

The clinical evidence for ashwagandha in women is unevenly distributed across conditions. The strongest data exist for stress reduction and menopausal symptoms, while fertility and PCOS evidence is thinner and largely mechanistic.

Menopause and perimenopausal symptoms

A randomized controlled trial in perimenopausal women found that 300 mg twice daily reduced hot flashes, night sweats, and anxiety scores compared to placebo (2020 rct). The mechanism is likely indirect: by lowering cortisol and modulating the HPA axis, ashwagandha reduces the stress-related exacerbation of vasomotor symptoms. Estrogen levels were not significantly altered, suggesting that benefits are mediated through stress pathways rather than direct hormonal replacement.

Fertility and ovulation

Direct evidence for ashwagandha improving female fertility is limited to mechanistic studies and case reports. One case report documented improved menstrual regularity in a woman with stress-induced amenorrhea, but this is anecdotal. The mechanism is plausible: by reducing cortisol, ashwagandha may restore normal GnRH pulsatility, which supports regular ovulation. However, this effect is most relevant in women whose cycles are disrupted by stress, not in those with structural or primary ovarian dysfunction.

Sperm quality data are far more robust. Multiple RCTs show improvements in sperm count, motility, and morphology in men with infertility, likely through antioxidant and testosterone-modulating effects. This does not directly translate to female fertility, but it suggests that antioxidant properties may protect gametes from oxidative damage in both sexes.

PCOS and metabolic effects

A small pilot study in women with PCOS found that 12 weeks of ashwagandha supplementation improved insulin sensitivity and reduced fasting glucose. The effect on insulin is mechanistically interesting: ashwagandha activates AMPK, a cellular energy sensor that improves glucose uptake, similar to metformin. However, the evidence base is not yet strong enough to recommend ashwagandha as a primary PCOS intervention.

How ashwagandha modulates the HPA and HPG axes

Chronic stress activates the hypothalamus to release corticotropin-releasing hormone (CRH), which signals the pituitary to secrete adrenocorticotropic hormone (ACTH), which in turn stimulates cortisol release from the adrenal glands. Elevated cortisol suppresses GnRH secretion from the hypothalamus, which reduces LH and FSH, disrupting ovulation and menstrual regularity.

Withanolides in ashwagandha appear to modulate CRH and ACTH secretion, reducing the downstream cortisol response. This restores normal GnRH pulsatility, which allows LH and FSH to rise to levels that support follicular development and ovulation. In women with stress-induced hypothalamic amenorrhea, this mechanism can restore menstrual cycles. In women with normal cycles, the effect is less pronounced.

Some studies show modest increases in thyroid hormone levels, particularly in subclinical hypothyroidism (2025 non-rct experimental). This is relevant because thyroid dysfunction is common in women and can disrupt menstrual cycles and fertility. However, women with hyperthyroidism or Graves' disease should avoid ashwagandha, as it may exacerbate thyroid overactivity.

Dose, form, and timing for women

Ashwagandha is available as root powder, root extract, and leaf extract. Root extract standardized to 5% withanolides is the most commonly studied form and the one used in clinical trials. Leaf extracts contain different withanolide profiles and are less well-researched. KSM-66 and Sensoril are two proprietary root extracts with clinical backing: KSM-66 is full-spectrum, while Sensoril is higher in withaferin A, a specific withanolide with anti-inflammatory effects.

Clinical research in women has tested various doses of standardized ashwagandha root extract. For stress and cortisol reduction, 600 mg daily appears to be the most effective dose (2022 meta-analysis). Lower doses (250 mg) may be sufficient for maintenance or mild stress, but higher doses are needed for clinically significant cortisol reduction.

Ashwagandha can be taken with or without food. Some users report mild sedation, so taking it in the evening may support sleep. Others find it energizing and prefer morning dosing. There is no evidence that timing significantly affects efficacy, so individual tolerance should guide the schedule. Ashwagandha is often combined with other adaptogens like rhodiola or holy basil, but there is no clinical evidence that combinations are superior to ashwagandha alone. For women with PCOS, combining ashwagandha with berberine or inositol may address insulin resistance more effectively, though this has not been formally tested.

Who benefits most and who should be cautious

Ashwagandha is most effective in women with elevated baseline cortisol or chronic stress. This includes:

• Women with stress-induced menstrual irregularities where high cortisol suppresses normal ovulation.
• Perimenopausal women with vasomotor symptoms exacerbated by stress and HPA axis dysregulation.
• Women with PCOS who have insulin resistance and inflammation driven by chronic stress.
• Women with subclinical hypothyroidism who may see modest thyroid hormone improvements.

Ashwagandha is not recommended during pregnancy. Animal studies suggest it may have abortifacient effects at high doses, and human safety data are insufficient (2023 meta-analysis). Women who are pregnant or trying to conceive should avoid it unless under medical supervision. Women with hyperthyroidism or Graves' disease should avoid ashwagandha, as it may increase thyroid hormone levels. Women on thyroid medication should monitor thyroid function if starting ashwagandha, as dose adjustments may be needed. Ashwagandha may interact with immunosuppressants, sedatives, and thyroid medications.

Perimenopausal and menopausal women appear to respond well to ashwagandha for symptom management. Younger women with regular cycles and low stress may see minimal hormonal effects. Women with primary ovarian insufficiency or structural infertility are unlikely to benefit, as ashwagandha does not replace missing ovarian function or correct anatomical issues.

Testing your hormonal status before and during supplementation

Ashwagandha's effects on hormones are most meaningful when baseline status is known. Testing cortisol, estradiol, progesterone, FSH, and LH before starting supplementation provides a reference point. Cortisol is best measured in the morning (when levels are highest) or via a four-point salivary cortisol test to assess diurnal rhythm. Elevated morning cortisol or a flattened diurnal curve suggests HPA axis dysregulation, which ashwagandha may address.

For women with menstrual irregularities, testing FSH and LH on cycle day 3 provides insight into ovarian reserve and hypothalamic-pituitary function. Low FSH and LH in the context of high cortisol suggest stress-related suppression, which ashwagandha may improve. For women with PCOS, testing fasting insulin, glucose, and HOMA-IR alongside testosterone and DHEA-S helps clarify whether metabolic or androgenic pathways are dominant.

Retesting after 8 to 12 weeks of supplementation shows whether ashwagandha is producing measurable hormonal changes. If cortisol normalizes but menstrual irregularities persist, other factors (thyroid dysfunction, prolactin elevation, structural issues) should be investigated. If cortisol remains elevated, the dose may need adjustment, or additional stress management interventions may be needed.

Getting objective data on your hormonal response

Ashwagandha is not a universal hormonal fix, and its effects depend on your baseline physiology. Most women supplementing ashwagandha are doing so without knowing whether their cortisol is actually elevated, whether their cycles are disrupted by stress or by another mechanism, or whether their symptoms are hormonal at all. Superpower's 100+ biomarker panel includes cortisol, estradiol, progesterone, FSH, LH, thyroid hormones, and inflammatory markers, giving you the full hormonal and metabolic context that determines whether ashwagandha is addressing a real imbalance or just masking symptoms. Testing before and after supplementation transforms guesswork into a personalized protocol grounded in your actual biology.